Biogen BIIB
NASDAQ BIIB
$217.15 +1.72 (+0.80%)
As of: Sep 11, 2026 · 3:59 PM EDT

Biogen (BIIB) Total Debt Growth (3y) (2012 - 2026)

Analysis

Biogen (BIIB) Total Debt Growth (3y) (2012 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt Growth (3y) (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn -0.51%
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn -0.71%
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn 0.08%
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn -
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn -
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn 8.78%
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn -
10 Insmed 28.06 Bn 26.90 Bn 358.27 Mn -22.30%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 8.78%
Mar 31, 2026 0.03%
Dec 31, 2025 0.03%
Sep 30, 2025 0.03%
Jun 30, 2025 -8.05%
Mar 31, 2025 -0.93%
Dec 31, 2024 -0.93%
Sep 30, 2024 -0.93%
Jun 30, 2024 -4.70%
Mar 31, 2024 -2.24%
Dec 31, 2023 -1.54%
Sep 30, 2023 -0.63%
Jun 30, 2023 -5.40%
Mar 31, 2023 -5.58%
Dec 31, 2022 -5.53%
Sep 30, 2022 -5.53%
Jun 30, 2022 11.64%
Mar 31, 2022 11.66%
Dec 31, 2021 11.69%
Sep 30, 2021 11.72%